A clinical study with 49 participants was started and completed at the height of the Covid-19 pandemic with the use of decentralized clinical trial (DCT) methodologies. All participants and the study team remained safe and were able to conduct the study efficiently. Patients were able to provide consent electronically, received experimental supplements and were given the option to provide feedback through the system’s telemedicine feature.
Key words: Decentralized clinical trials DCT, LUTS Lower Urinary Tract Symptoms
- Center for Drug Evaluation, Research. Electronic Source Data in Clinical Investigations [Internet]. U.S. Food and Drug Administration. FDA; [cited 2022 Oct 28]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-source-data-clinical-investigations
- Török ME, Underwood BR, Toshner M, Waddington C, Sidhom E, Sharrocks K, et al. Challenges and opportunities for conducting a vaccine trial during the COVID-19 pandemic in the United Kingdom. Clinical Trials [Internet]. 2021 Jun 22;18(5):615–21. Available from: http://dx.doi.org/10.1177/17407745211024764
- Why decentralized clinical trials remain a black box to most research sites [Internet]. Contract Pharma. [cited 2022 Oct 28]. Available from: https://www.contractpharma.com/contents/view_experts-opinion/2022-03-18/why-decentralized-clinical-trials-remain-a-black-box-to-most-research-sites/%20ief%20Clinical%20Trial%20Officer%20at%20Florence%20Healthcare03.18.22
- Deloitte Report 2022. Reimagining clinical trials in the age of the digital patient. Deloitte.com. [cited 2022 Oct 28]. Available from: https://www2.deloitte.com/content/dam/Deloitte/us/Documents/life-sciences-health-care/us-lshc-envisioning-digital-trials-new.pdf
Articles related to the one you are viewing
There are currently no results to show, please try again later
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.